Načítá se...
The development of immunoconjugates for targeted cancer therapy
Immunoconjugates are specific, highly effective, minimally toxic anticancer therapies that are beginning to show promise in the clinic. Immunoconjugates consist of three separate components: an antibody that binds to a cancer cell antigen with high specificity, an effector molecule that has a high c...
Uloženo v:
| Vydáno v: | Nat Rev Clin Oncol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4700536/ https://ncbi.nlm.nih.gov/pubmed/25265912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2014.159 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|